Damora Therapeutics, Inc. cotiza a 20.25 USD y tiene una capitalización bursátil de $1.3B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; a…
| Periodo | 2026-11 | 2026-08 | 2025-03 | 2024-11 |
|---|---|---|---|---|
| Real | — | $-0.39 | $-5.00 | $-3.39 |
| Estimado | $-0.40 | $-0.37 | $-2.82 | $-3.70 |
| Sorpresa | — | -5.4% | -77.3% | +8.4% |
| Métrica | DMRA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -87.3% | -40.4% | -46.9% |
| ROA | -80.5% | -32.0% | -48.5% |
| Current Ratio | 12.98 | 2.84 | +10.14 |
| Debt / Equity | — | 0.28 | — |